Axillary Lymphadenopathy as an Initial Presentation of Systemic Amyloidosis: A Case Report and Literature Review
- PMID: 36300416
- PMCID: PMC9619915
- DOI: 10.1177/23247096221133191
Axillary Lymphadenopathy as an Initial Presentation of Systemic Amyloidosis: A Case Report and Literature Review
Abstract
Amyloidosis rarely presents as localized lymphadenopathy. Various studies have elucidated the varied presentation and manifestations of this interesting disease. We reviewed the literature and found 36 cases of primary amyloidosis with lymph node enlargement as a presentation, and 17 of the 36 cases (47%) had systemic involvement on further work up. We describe a patient who presented with an isolated right axillary mass. Clinical examination and radiology were indicative of a lymph node enlargement with no evidence of malignancy in the breasts or lungs. Histopathological examination was indicative of amyloidosis. A further work up including serum, urine biochemistry, cardiac work up, bone marrow examination, and a kidney biopsy revealed systemic amyloidosis. Patient was treated with daratumumab and CyBorD (cyclophosphamide, bortezomib, and dexamethasone) followed by a stem cell transplantation. Patient is in remission for 1 year, at the time of submission of this report. Therefore, we conclude (1) systemic amyloidosis presenting as an isolated lymph node enlargement is rare, (2) a structured systemic work up is imperative for early diagnosis and proper management of amyloidosis, when there is an index of suspicion, and (3) use of novel therapeutic options such as CD38 + antibody (daratumumab) and stem cell transplant have positive impact on disease outcomes.
Keywords: AL amyloidosis; axillary lymph node; lymph node; lymphadenopathy.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures


Similar articles
-
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.Drugs. 2022 Apr;82(6):683-690. doi: 10.1007/s40265-022-01705-3. Drugs. 2022. PMID: 35416593 Review.
-
Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.Am J Case Rep. 2021 Aug 23;22:e933241. doi: 10.12659/AJCR.933241. Am J Case Rep. 2021. PMID: 34421115 Free PMC article.
-
Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.Eur J Neurol. 2023 Mar;30(3):745-748. doi: 10.1111/ene.15640. Epub 2022 Nov 28. Eur J Neurol. 2023. PMID: 36403110 Free PMC article.
-
[Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].Rev Med Interne. 2022 Nov;43(11):673-676. doi: 10.1016/j.revmed.2022.07.013. Epub 2022 Aug 5. Rev Med Interne. 2022. PMID: 35934598 French.
-
Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation.Am J Med. 2022 Apr;135 Suppl 1:S30-S37. doi: 10.1016/j.amjmed.2022.01.011. Epub 2022 Jan 23. Am J Med. 2022. PMID: 35081382 Review.
Cited by
-
Breast calcifications on mammography from systemic amyloidosis: A case report.Radiol Case Rep. 2024 Jun 17;19(9):3740-3747. doi: 10.1016/j.radcr.2024.05.083. eCollection 2024 Sep. Radiol Case Rep. 2024. PMID: 38983295 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials